Day

June 11, 2018
Administering carfilzomib once a week significantly improves progression-free survival (PFS) and toxicity compared with twice a week among patients with relapsed/refractory multiple myeloma (RRMM), according to a study published in The Lancet Haematology.1 Carfilzomib twice weekly is currently approved for the treatment of RRMM but is associated with significant burden to both patients and caregivers as treatment...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand